US 9551713
Use of a panel of urinary cytokines to predict response to BCG therapy for bladder cancer
granted A61KA61K35/74A61P
Quick answer
US patent 9551713 (Use of a panel of urinary cytokines to predict response to BCG therapy for bladder cancer) held by The Board of Regents of the University of Texas System expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K35/74, A61P, A61P35/00